Clinical trials: Aripiprazole, active
Depression, Sequestra
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
This project aims to investigate the effectiveness of existing common antidepressants and to provide new evidence for depressed children and adolescents who are not responding to their first treatment.
- Trial name
- STAR-AD (NCT05814640)
- Testing
- Fluoxetine, Sertraline, Vortioxetine
- Where
- China
- Volunteers
- 520 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Schizophrenia
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed…
- Trial name
- NCT07703956
- Testing
- VV119 2mg, VV119 4mg, VV119 6mg
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Vigonvita Life Sciences
Acute Schizophrenia
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
This is a non-Inferiority trial to evaluate efficacy and safety of hydrochloride carliprazine capsules and aripiprazole tablets in treating acute schizophrenia in Chinese adults.
- Trial name
- NCT06589817
- Testing
- Hydrochloride Carliprazine capsules, Aripiprazole tablets
- Volunteers
- 376 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Schizophrenia
Study on the Efficacy and Safety of QLM1016 in Schizophrenia
The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.
- Trial name
- NCT06799559
- Testing
- 3-6mg QLM1016, 10-20 mg Aripiprazole oral solution film
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Major Depressive Disorder (MDD)
Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)
This project aims to investigate the effectiveness of existing common antidepressants in adolescents with MDD who did not respond to their first treatment.
- Trial name
- SMART-I (NCT07011693)
- Testing
- Sertraline, Agomelatine, Aripiprazole
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Xinyu Zhou
Bipolar Disorder
Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area
It is the purpose of this pilot study to evaluate a high-fat/low-carbohydrate "ketogenic" diet-based intervention as an adjunctive strategy for impacting symptoms of bipolar disorder.
- Trial name
- NCT07570875
- Testing
- Ketogenic foodstuffs, Standard of Care Oral antipsychotics, Standard of care long acting injectable medication for bipolar disorder
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Challenging Behavior, Autism Spectrum Disorder
Measurement of Treatment Effects
The overall objective is to evaluate and compare the efficacy of two common treatments for CB in children and adolescents with autism using multiple outcome measures.
- Trial name
- NCT07024303
- Testing
- Psychotropic medication (at discretion of psychiatrist), Behavioral therapy
- Volunteers
- 20 people
- Sponsor
- Matthew J O'Brien, PhD, BCBA-D
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
SCHIZOPHRENIA 1 (Disorder)
Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults
This is a Phase 3, randomized, double-blind, parallel-group, active- and placebo-controlled, multicenter inpatient study to examine the efficacy and safety of HS-10380 in adult Participants who are acutely psychotic with a…
- Trial name
- NCT07911787
- Testing
- HS-10380, Aripiprazole
- Where
- China
- Volunteers
- 476 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Psychosis; Acute
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and…
- Trial name
- CINEMA (NCT07483294)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Northwell Health
Schizophrenia
Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.
The primary objective of this study is to evaluate the bioequivalence of aripiprazole for injection (Test product, 400 mg) compared with Abilify Maintena® (Reference product, 400 mg) at steady state in patients with…
- Trial name
- NCT07547384
- Testing
- Aripiprazole for Injection
- Volunteers
- 116 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Psychosis
Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study
Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in…
- Trial name
- NCT03442101
- Testing
- Patients with psychosis will be treated with known antipsychotic medication
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- University of Alabama at Birmingham
Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder
The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.
The goal of this clinical trial is to test whether a personalized approach to treatment selection improves symptoms in older adults with treatment-resistant depression.
- Conditions
- Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- BAARD (NCT07810738)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation
- Where
- 3 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Depression
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
The goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression.
- Trial name
- CLIMB (NCT06591091)
- Testing
- Clemastine Fumarate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Illinois Chicago
Psychosis, Negative Symptoms With Primary Psychotic Disorder
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Antipsychotics affects the brain's dopamine system, and the drugs reduce delusions, hallucinations, and disorganized thinking, which are cardinal symptoms of psychotic disorders. However, negative symptoms e.g.
- Trial name
- AMEND (NCT04789915)
- Testing
- Memantine
- Where
- Denmark
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bjorn H. Ebdrup
Treatment-resistant Schizophrenia
Sequential Treatment Approaches for Treatment-Resistant Schizophrenia
The goal of this study is to optimize treatment strategies for Chinese patients with treatment-resistant schizophrenia (TRS). It will compare two types of treatment: 1.
- Trial name
- STATRS (NCT07918222)
- Testing
- [Phase 1] Clozapine, [Phase 1] Aripiprazole, [Phase 1] Amisulpride
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Mental Health Center
Pregnant Women, Psychotropic Drugs
National Pregnancy Registry for Psychiatric Medications
The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many…
- Trial name
- NCT01246765
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Apathy, Schizophrenia
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician …
- Conditions
- Apathy, Schizophrenia, Schizophrenia; Psychosis
- Trial name
- NCT06482554
- Testing
- Lumateperone 42 mg, Risperidone 2 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Trichotillomania (Hair-Pulling Disorder), Dermatillomania
Aripiprazole in Body Focused Repetitive Behaviors
This study is 6 weeks long and involves subjects taking aripiprazole or placebo. If they are randomly assigned to the aripiprazole arm and are eligible to participate in the study, they will begin by taking 5mg once daily of…
- Trial name
- NCT05545891
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Chicago
Schizophrenia, Bipolar Affective Disorder
Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in…
- Trial name
- NCT07858565
- Testing
- Quetiapine (drug), quetiapine + aripiprazole, quetiapine + haloperidol
- Where
- Bosnia and Herzegovina
- Volunteers
- 500 people
- Sponsor
- Bosnalijek D.D